Pengaruh Pemberian Active Hexose Correlated Compound (AHCC) Terhadap Kadar Interleukin-6 Pada Pasien Kanker Paru Karsinoma Bukan Sel Kecil Yang Dilakukan Kemoterapi

Abstract

Introduction: IL‐6 is a cytokine that plays an important role in response to injury or infection and is a promising biomarker for predicting poor prognosis and therapeutic targets in non‐small cell lung cancer (NSCLC) and Active Hexose Correlated Compound is a nutritional supplement that has antioxidant, anti-inflammatory, and immunostimulatory effects, as well as hepatoprotective properties that are useful for cancer patients and is expected to be useful in lowering IL-6 levels. Objectives: To determine the effect of Active Hexose Correlated Compound (AHCC) administration on Interleukin-6 levels in patients with Non-Small Cell Lung Cancer undergoing chemotherapy. Methodology: This research was a true experimental study with a triple-blind randomized controlled trial design among Non-Small Cell Lung Cancer (NSCLC) patients. Blood sampling was used with serum. ELISA platform (semi-quantitative) was used to rate IL-6 serum. The data of serum levels collected and statistically analyzed. Results: Results of 50 samples Non-Small Cell Lung Cancer (NSCLC), we found the IL-6 levels of NSCLC patients who consumed AHCC after chemotherapy showed an increase in the abnormal range in 25 samples (100%), and none of the IL-6 levels remained within the normal range. The IL-6 levels of NSCLC patients who consumed placebo after chemotherapy showed an abnormal increase in 25 samples (100%), and none of the IL-6 levels remained within the normal range. Conclusions: The potential of AHCC to manage IL-6 levels in lung cancer could translate into a complementary therapy to standard treatment, potentially improving patient outcomes by reducing inflammation and tumor growth.